Your immune system.
Our science.
Stopping cancer.

Our Approach
3

Target CD47 Differently

ADVANCING A HIGHLY-DIFFERENTIATED ANTI-CD47 ANTIBODY TO TREAT CANCER

At Arch Oncology, we discover and develop new biologic therapeutics to treat patients living with cancer. We are committed to advancing antibodies with best-in-class potential.

Our lead molecule, AO-176, is an IgG2 CD47 targeted antibody, which blocks the “do not eat me” signal enabled by CD47’s interaction with SIRPa and induces phagocytosis.

In addition, AO-176 exhibits:

  • Lower binding to normal cells in general and negligible binding to red blood cells
  • Enhanced binding to CD47 at acidic pH found in tumor microenvironments
  • Programmed and immunogenic cell death

These highly differentiated features of AO-176 offer a potential best-in-class profile

Arch Oncology has two bases. Our headquarters is in Brisbane, CA, a gateway of biotechnology innovation, and our scientific research laboratory is in St. Louis, MO, home of the Gateway Arch.